Summit Therapeutics Valuation

Is SMMT * undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SMMT * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SMMT *'s fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SMMT *'s fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SMMT *?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for SMMT *. This is calculated by dividing SMMT *'s market cap by their current preferred multiple.
What is SMMT *'s n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	n/a

SMMT * key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	-86x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does SMMT *'s PB Ratio compare to its peers?

The above table shows the PB ratio for SMMT * vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	3.3x
BNTX BioNTech	1.3x	7.6%	US$26.5b
MRNA Moderna	1.4x	18.1%	US$18.0b
XENE Xenon Pharmaceuticals	4x	15.3%	US$3.4b
RVMD Revolution Medicines	6.5x	7.2%	US$10.2b
SMMT * Summit Therapeutics	36.7x	n/a	Mex$16.1b

Price-To-Book vs Peers: SMMT * is expensive based on its Price-To-Book Ratio (36.7x) compared to the peer average (3.3x).

Price to Earnings Ratio vs Industry

How does SMMT *'s PE Ratio compare vs other companies in the Global Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	0%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	0%
	n/a	n/a	n/a

No more companies

Price-To-Book vs Industry: SMMT * is expensive based on its Price-To-Book Ratio (36.7x) compared to the Global Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is SMMT *'s PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SMMT * PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	36.7x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate SMMT *'s Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SMMT * forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	n/a	Mex$698.05 0%	22.8%	Mex$881.56	Mex$465.59	n/a	4
Nov ’25	Mex$374.00	Mex$720.13 +92.5%	25.2%	Mex$886.41	Mex$468.15	n/a	3
Oct ’25	n/a	Mex$714.16 0%	26.7%	Mex$900.71	Mex$452.36	n/a	3
Sep ’25	Mex$258.50	Mex$282.48 +9.3%	7.4%	Mex$309.82	Mex$258.63	n/a	3
Aug ’25	n/a	Mex$241.83 0%	2.6%	Mex$248.13	Mex$235.52	n/a	2
Jul ’25	n/a	Mex$240.00 0%	3.4%	Mex$248.27	Mex$231.73	n/a	2
Jun ’25	n/a	Mex$178.42 0%	23.8%	Mex$220.91	Mex$135.94	n/a	2

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.